/4598.T
4598.T Stock - Delta-Fly Pharma, Inc.
Healthcare|BiotechnologyJPX
$257.00-4.10%
$11.00 (-4.10%) • Jan 16
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.6
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $282.70
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for 4598.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$254.43 – $259.57
TARGET (TP)$295.55
STOP LOSS$236.44
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.85
52W High$793.00
52W Low$248.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $300.00M | $300.00M |
| Gross Profit | $-1,588,000 | $-1,512,000 | $-1,632,000 | $300.00M | $300.00M |
| Gross Margin | N/A | N/A | N/A | 100.0% | 100.0% |
| Operating Income | $-1,708,223,000 | $-1,403,464,000 | $-1,315,810,000 | $-961,462,000 | $-852,231,000 |
| Net Income | $-1,721,164,000 | $-1,429,393,000 | $-1,328,788,000 | $-967,302,000 | $-862,585,000 |
| Net Margin | N/A | N/A | N/A | -322.4% | -287.5% |
| EPS | $-195.58 | $-198.80 | $-234.51 | $-178.58 | $-187.34 |
Company Overview
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
4598.TBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-41.61
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-41.61 | — | — |
Q3 2025 | Aug 8, 2025 | — | $-35.43 | — | — |
Q2 2025 | May 15, 2025 | — | $-45.79 | — | — |
Q1 2025 | Feb 11, 2025 | — | $-43.20 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-50.67 | — | — |
Q3 2024 | Aug 9, 2024 | — | $-60.76 | — | — |
Q2 2024 | May 15, 2024 | — | $-55.52 | — | — |
Q1 2024 | Feb 13, 2024 | — | $-49.81 | — | — |
Q4 2023 | Nov 13, 2023 | — | $-48.84 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-43.07 | — | — |
Q2 2023 | May 15, 2023 | — | $-46.21 | — | — |
Q1 2023 | Feb 14, 2023 | — | $-75.09 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-57.93 | — | — |
Q3 2022 | Aug 12, 2022 | — | $-56.96 | — | — |
Q2 2022 | May 13, 2022 | — | $-23.95 | — | — |
Q1 2022 | Feb 14, 2022 | — | $-51.72 | — | — |
Q4 2021 | Nov 11, 2021 | — | $-46.28 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-56.76 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-17.88 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-67.29 | — | — |
Latest News
Loading news...
Frequently Asked Questions about 4598.T
What is 4598.T's current stock price?
Delta-Fly Pharma, Inc. (4598.T) is currently trading at $257.00 per share. The stock has moved -4.10% today.
What is the analyst price target for 4598.T?
No analyst price targets are currently available for this stock.
What sector is Delta-Fly Pharma, Inc. in?
Delta-Fly Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the JPX exchange.
What is 4598.T's market cap?
Delta-Fly Pharma, Inc. has a market capitalization of $2.95 billion, making it a mid-cap company.
Does 4598.T pay dividends?
No, Delta-Fly Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare Sector206A.T
PRISM BioLab Co.,LTD
$185.00
Mkt Cap: $6.8B
2342.T
Trans Genic Inc.
$299.00
Mkt Cap: $5.0B
2385.T
Soiken Holdings Inc.
$268.00
Mkt Cap: $7.0B
4570.T
Immuno-Biological Laboratories Co., Ltd.
$1684.00
Mkt Cap: $15.7B
4572.T
Carna Biosciences, Inc.
$417.00
Mkt Cap: $8.0B
4576.T
D. Western Therapeutics Institute, Inc.
$103.00
Mkt Cap: $4.6B
4591.T
Ribomic Inc.
$88.00
Mkt Cap: $4.5B
4596.T
Kubota Pharmaceutical Holdings Co., Ltd.
$48.00
Mkt Cap: $2.9B
4881.T
FunPep Company Limited
$89.00
Mkt Cap: $3.6B
4884.T
Kringle Pharma, Inc.
$419.00
Mkt Cap: $3.0B
Explore stocks similar to 4598.T for comparison